Navigation Links
New Study Finds Targeted Treatment Can Significantly Reduce Relapse Risk In High-Risk Children With Acute Myeloid Leukemia
Date:12/9/2013

KANSAS CITY, Mo., Dec. 9, 2013 /PRNewswire/ -- The addition of a monoclonal antibody called gemtuzumab combined with standard chemotherapy has been shown to significantly reduce the risk of relapse and increase rates of disease-free survival in pediatric patients with acute myeloid leukemia (AML). Post-treatment relapse rates are a major indicator of potential for long-term survival in children with the disease.

(Logo: http://photos.prnewswire.com/prnh/20130904/NY73838LOGO )

The study (abstract #355) evaluated a total of 1,022 children averaging 10 years old at trial sites nationwide, led by Alan Gamis, MD, MPH, Associate Division Director, Section of Oncology at Children's Mercy Hospital in Kansas City. It will be highlighted in an oral presentation Monday, Dec. 9, at the American Society of Hematology annual meeting in New Orleans.

"Chemotherapy has limits. Particularly in children, increasing doses further can become too toxic for the patient while still not achieving the desired effect on the cancer," said Dr. Gamis. "This study is significant because it shows for the first time that this targeted treatment can augment the effects of chemotherapy in children and effectively reduce their risk of relapse. We found it was most effective in the patients most at risk."

Gemtuzumab was removed from the U.S. market in 2010 because the U.S. Food and Drug Administration determined the potential risks of the drug outweighed the potential benefits. Recent research with the compound has raised questions about whether that action may have been premature. This data supports recent findings in adults with AML that gemtuzumab reduced their risk of relapse when added to standard chemotherapy.

"This could be an important treatment option for critical patients," said Dr. Gamis. "Gemtuzumab appears to have a real impact in increasing the likelihood of long-term survival in high-risk patients."

In this study, patients were treated with gemtuzumab or a standard treatment regimen. Compared with standard regimens, the addition of gemtuzumab was associated with better disease-free survival (61 vs. 55%) and reduced relapse risk (33 vs. 41%). It did not significantly improve overall survival (74 vs. 70%).

Chat Live with Dr. Gamis 
Dr. Gamis will discuss this study and answer questions about pediatric oncology from medical professionals, media and the public via Twitter at 1 p.m. Central (2 p.m. Eastern) on Friday, Dec. 20, through the @ChildrensMercy account. Join the conversation by including #cancerchat and @ChildrensMercy in tweets.

About Children's Mercy Hospital 
Children's Mercy, located in Kansas City, Mo., is one of the nation's top pediatric medical centers. The 354-bed hospital provides care for children from birth through the age of 21, and has been ranked by U.S. News & World Report as one of "America's Best Children's Hospitals" and recognized by the American Nurses Credentialing Center with Magnet designation for excellence in nursing services. Its faculty of 600 pediatricians and researchers across more than 40 subspecialties are actively involved in clinical care, pediatric research, and educating the next generation of pediatric subspecialists. For more information about Children's Mercy and its research, visit childrensmercy.org or download our mobile phone app CMH4YOU for all phone types. For breaking news and videos, follow us on Twitter, YouTube and Facebook.


'/>"/>
SOURCE Children's Mercy Hospital
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Heptares Initiates Clinical Study With First Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Patients With Alzheimers Disease
2. Shire Reports Top-Line Results on OPUS-2, a Phase 3 Study Investigating the Use of Lifitegrast (5.0% Ophthalmic Solution) in Adults With Dry Eye Disease
3. Third Clinical Study Confirms Treatment Guided By GeneSight Psychiatric Pharmacogenomics Test
4. Study Confirms Efficacy of Innovative Therapies Quantum Negative Pressure Wound Therapy (NPWT) in Enhancing Wound Healing
5. Annual General Meeting Schedules, New Drug Applications, Positive Study Results, Conference Participations, and Secondary Offerings - Research Report on Mindray, AcelRx, Merrimack, ZELTIQ, and Clovis
6. 3-V Biosciences Commences Patient Dosing in Phase 1 Clinical Study of FASN Inhibitor TVB-2640 in Patients with Advanced Solid Tumors
7. RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period
8. Lexicon Completes Phase 2 Study Of LX1033 In IBS-d
9. Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Says New Study Adds to Debate Surrounding Robotic Surgery
10. Burzynski Clinic Presents the Results of a Phase II Study of Antineoplastons in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma at the Congress
11. New Study Evaluates Psychotropic Prescribing For Persons with Intellectual Disabilities, Other Psychiatric Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent specialty ... 2017.  All comparisons, unless otherwise noted, are to the quarter ... Second Quarter 2017 Highlights include: ... of 3.5% Total prescriptions dispensed of 220,000, ... versus 7.6% Gross profit per prescription ...
(Date:8/4/2017)...  Agragen, LLC, a Cincinnati ... nutraceutical, and aquacultural feed sectors, announces a significant ... candidates, AGR131.  This drug is designed to trap ... of patients suffering from inflammatory conditions such as ... Biological pharmaceuticals currently ...
(Date:8/2/2017)... and BENTON, Ky. , Aug. 2, 2017   Marshall County ... its environmental services (ES) team to proactively reduce the risk of hospital-acquired infections (HAIs). The ... disinfection robot that uses UVC light energy to kill deadly pathogens such as C. ... Tru-D SmartUVC ... Tru-D in action in ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... August 22, 2017 , ... Although Labor Day is not ... communities have begun providing weekend displays, and numerous households celebrate the unofficial end of ... be downright terrifying for pets. , Kris Zambo, owner of Dynamite Fireworks ...
(Date:8/21/2017)... , ... August 22, 2017 , ... ... not without risk to health and safety. By learning and implementing best practices ... , In this webinar, attendees will gain a better understanding of a ...
(Date:8/21/2017)... ... August 21, 2017 , ... Los Angeles area medical ... for academic year 2017-2018, Christina M. Busuito, M.D. and Lukasz Swistun, M.D. This ... Plastic and Reconstructive Surgery. The candidate will have the opportunity to work ...
(Date:8/21/2017)... ... August 21, 2017 , ... ... it has become the Official Technology Partner of North Country Region Volleyball and ... Event Systems) volleyball software, along with providing sport management software to their member ...
(Date:8/21/2017)... ... August 21, 2017 , ... Marathon running has ... the country. , Outdoor running increases exposure to ultraviolet radiation, a carcinogen that ... of melanoma, and only half may be adequately protecting themselves with proper clothing ...
Breaking Medicine News(10 mins):